Acurable Limited news

AcuPebble SA100 is clinically equivalent to cardiorespiratory polygraphy for the automated diagnosis of obstructive sleep apnea (OSA) at home, a paper published in the BMJ Open has revealed. A powered clinical trial conducted by the Royal Free Hospital in London demonstrated both the accuracy and usability of the small device, which has the potential to open more efficient patient pathways for OSA diagnosis.

Currently, OSA diagnosis in the UK uses either full polysomnography or limite

AcuPebble SA100, a small wearable device that enables automated, remote home testing to detect obstructive sleep apnoea (OSA) in adults, has obtained FDA 510(k) clearance as a Class II medical device in the USA. The device, which received a CE Mark as a Class IIa medical device in 2020, was developed and is commercialised by UK-based medical device company Acurable and builds on more than ten years of research led by Professor Esther Rodriguez-Villegas at the Wearable Technologies Lab in Impe

Acurable, a fast-growing medical device company, has announced the availability of its first product, AcuPebble SA100, a small wearable device which for the first time enables a fully automated and remote diagnosis of obstructive sleep apnoea (OSA). Traditionally, the diagnosis of OSA has required multiple hospital visits for patients, and doctors have had to manually review and analyse data from a patient’s sleep study. AcuPebble SA100 automates this process, instantly providing a clin

AcuPebble SA100, the first medical device to obtain the CE mark for the automated diagnosis of Obstructive Sleep Apnoea, has been announced as one of 12 exciting innovations to join the NHS Innovation Accelerator 2021. This award-winning programme identifies early-stage solutions which address the most pressing needs of the NHS, and supports them over three years as they scale across England for the benefit of NHS patients and staff.

This year, the NIA’s rigorous, multi-stage se